Immune Targeting Systems (ITS) Ltd. Announces Positive Phase I Data for Flunisyn™, Its Pan-Strain Influenza A T-Cell Vaccine, and Changes to the Company's Senior Management Team
Published: Sep 17, 2012
LONDON--(BUSINESS WIRE)--Immune Targeting Systems Limited (“ITS”), an emerging leader in the development of vaccines that promote T-cell responses against viruses and cancers, today announces compelling data from two Phase I clinical trials of FlunisynTM, the Company’s lead vaccine programme which elicits potent immune responses against multiple strains of influenza-A virus. ITS also announces the appointments of Dr. Benjamin Chen, Executive Chairman and Dr. Kevin FitzGerald, Chief Operating Officer, to support the Company as it moves towards commercialisation of its products and technologies.